Medscape and IMF Partnership: Panel Discussion on CD38-Targeted Therapy for Multiple Myeloma
From tailored quadruplet regimens to innovative delivery systems, discover the patient-centric future of multiple myeloma treatment.
Read the full articleYou might also wanna read
<![CDATA[Rationale and Timing: The Evolving Role of BCMA-Targeted Therapies in Relapsed/Refractory Multiple Myeloma ]]>
Pharmacy Times·20h ago
A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma
Conditions : Relapsed or Refractory Multiple Myeloma Interventions : Biological: AZD4045; Drug: Daratumumab; Drug: Aldesleukin Sponsors : As
clinicaltrials.gov·8d ago
Rethinking Your Approach To Capacity Building with the Multiple Myeloma Research Foundation’s Diana Perrault
In our Season 5 finale, The Multiple Myeloma Research Foundation’s Diana Perrault joins the podcast to share how leaders can rethink capacit
trustory.fm·7mo ago
<![CDATA[Outpatient BiTE Therapy Model Expands Access for Patients With Multiple Myeloma]]>
Pharmacy Times·2d ago
Real-World Clinical Outcomes in Relapsed/Refractory Multiple Myeloma Treated With Pomalidomide Regimens
Conditions : Relapsed/Refractory Multiple Myeloma Interventions : Drug: Pomalidomide-containing regimens; Drug: Non-pomalidomide-containing
clinicaltrials.gov·3d ago
CAR-T in Relapsed/Refractory Multiple Myeloma
Conditions : Multiple Myeloma Refractory; Multiple Myeloma in Relapse Interventions : Biological: CAR-T Sponsors : Dr. Zaineb Akram Recruiti
clinicaltrials.gov·2d ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.